- Home
- TYRA
as 04-18-2025 1:44pm EST
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are TYRA-300, TYRA-200, and TYRA-430: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | CARLSBAD |
| Market Cap: | 422.6M | IPO Year: | 2021 |
| Target Price: | $30.50 | AVG Volume (30 days): | 353.6K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.51 | EPS Growth: | N/A |
| 52 Week Low/High: | $6.42 - $29.60 | Next Earning Date: | 05-08-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Tyra Biosciences Inc. (TYRA)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Kjellson Nina S | TYRA | Director | Feb 5 '25 | Sell | $13.76 | 5,401 | $74,323.70 | 3,700,705 | |
| Kjellson Nina S | TYRA | Director | Jan 23 '25 | Sell | $16.26 | 4,825 | $78,466.08 | 3,700,705 |
Latest Tyra Biosciences Inc. News
TYRA Breaking Stock News: Dive into TYRA Ticker-Specific Updates for Smart Investing
Simply Wall St.
21 days ago
Companies Like Tyra Biosciences (NASDAQ:TYRA) Are In A Position To Invest In Growth
PR Newswire
22 days ago
Tyra Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights
PR Newswire
2 months ago
Tyra Biosciences to Present at Upcoming Investor Conferences
PR Newswire
3 months ago
Tyra Biosciences Announces Appointment of Adele Gulfo to Board of Directors
Simply Wall St.
3 months ago
Private equity firms account for 44% of Tyra Biosciences, Inc.'s (NASDAQ:TYRA) ownership, while institutions account for 33%
PR Newswire
3 months ago
Tyra Biosciences Announces Poster Presentations at 2025 ASCO Gastrointestinal Cancers Symposium
MT Newswires
3 months ago
Tyra Biosciences Insider Sold Shares Worth $409,645, According to a Recent SEC Filing
MT Newswires
3 months ago
Tyra Biosciences' TYRA-300 Gets US FDA Clearance for Phase 2 Trial in Non-Muscle Invasive Bladder Cancer
Compare TYRA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TYRA Tyra Biosciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.